Effect of the Lupus Anticoagulant on Endothelial Fibrinolytic Activity In Vitro

Summary

We investigated the effect of plasma and serum from 10 subjects with the lupus anticoaguiant and thrombosis and 9 normal subjects on the secretion of tissue-type plasminogen activator (t-PA) and its rapid inhibitor (type 1 plasminogen activator inhibitor, or PAI-1) by cultured human endothelial cells. Confluent monolayers of human umbilical vein endothelial cells were incubated for 48 hours with plasma or serum diluted ten-fold in serum-free endothelial cell growth medium, and the secretion of t-PA and PAI-1 measured by enzyme-linked immunosorbent assay. No consistent differences in mean t-PA and PAI-1 release were found between cells exposed to normal plasma or serum and plasma or serum from subjects with the lupus anticoagulant and thrombosis. No plasma or serum sample produced consistent inhibition of t-PA release or stimulation of PAI-1 release (defined as t-PA levels less than the mean minus two standard deviations for normal subjects, and PAI-I- levels greater than the mean plus two standard deviations for normal subjects, respectively). These findings do not support a role for altered endothelial fibrinolytic activity in the pathogenesis of thrombosis in subjects with the lupus anticoagulant, and are consistent with previous observations that these subjects have normal fibrinolytic activity in vivo.

Keywords

Fibrinolysis - Thrombosis - Lupus anticoagulant - Antiphospholipid antibodies - Endothelium

• References

• 1 Bowie EJ W, Thompson JH, Pascuzzi CA, Owen CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963; 3: 416-430
• 2 Mueh JR, Herbst KD, Rapaport SI. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med 1980; 92: 156-159
• 3 Elias M, Eldor A. Thromboembolism in patients with the “lupus”-type circulating anticoagulant. Arch Intern Med 1984; 144: 510-515
• 4 Boey M, Colaco CC, Gharavi AE, Elkon KB, Loizou S, Hughes GR V. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J 1983; 287: 1021-1023
• 5 Fisher M, McGehee W. Cerebral infarct, TIA, and lupus inhibitor. Neurology 1986; 36: 1234-1237
• 6 Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes GR V. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2: 1211-1214
• 7 Hamsten A, Norberg R, Bjorkholm M. et al Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986; 1: 113-116
• 8 Morton KE, Gavaghan TP, Krilis SA. et al Coronary artery bypass graft failure - an autoimmune phenomenon. Lancet 1986; 2: 1353-1357
• 9 Carreras LO, Defreyn G, Machin SS, Vermylen J, Deman R, Spitz B, Van Assche A. Arterial thrombosis, intrauterine death and “lupus” anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981; 1: 244-266
• 10 Carreras LO, Vermylen JG. “lupus” anticoagulant and thrombosis - possible role of inhibition of prostacyclin formation. Thromb Haemo-stas 1982; 48: 38-40
• 11 Comp PC, DeBault LE, Esmon NL, Esmon CT. Human thrombomodulin is inhibited by IgG from two patients with nonspecific anticoagulants. Blood 1983; 62: 299 a (Abstr)
• 12 Cariou R, Tobelem G, Soria C, Caen J. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med 1986; 314: 1193-1194 (Letter)
• 13 Freyssinet JM, Wiesel ML, Gauchy J, Boneu B, Cazenave JP. An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity. A mechanism for thrombosis Thromb Haemostas 1986; 55: 309-313
• 14 Angles-Cano E, Sultan Y, Clauvel J-P. Predisposing factors to thrombosis in systemic lupus erythematosus. Possible relation to endothelial cell damage J Lab Clin Med 1979; 94: 312-323
• 15 Stalder M, Hauert J, Kruithof EK O, Bachmann F. Release of vascular plasminogen activator (v-PA) after venous stasis: elec-trophoretic-zymographic analysis of free and complexed v-PA. Br J Haematol 1985; 61: 169-176
• 16 Wiman B, Ljungberg B, Chmielewska J, Urden G, Blomback M, Johnsson H. The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med 1985; 105: 265-270
• 17 Juhan-Vague I, Valadier J, Alessi MM, Aillaud MF, Ansaldi J, Philip-Joet C, Holvoet P, Serradimigni A, Collen D. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemostas 1987; 57: 67-72
• 18 Hamsten A, Wiman B, DeFaire U, Blombäck M. Increased levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563
• 19 Paramo JA, Colucci M, Collen D. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 1985; 291: 573-574
• 20 Francis Jr RB, Kawanishi D, Baruch T, Mahrer P, Rahimtoola S, Feinstein DI. Impaired fibrinolysis in coronary artery disease. Am Heart J 1988; 115: 776-780
• 21 Francis Jr RB, McGehee WW, Feinstein DI. Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis. Thromb Haemostas 1988; 59: 412-414
• 22 Exner T, Richard KK, Kronenberg H. A sensitive test demonstrating the lupus anticoagulant and its behavioral patterns. Br J Haematol 1978; 40: 143-150
• 23 Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria J Clin Invest 1973; 52: 2745-2756
• 24 Jaffe EA, Hoyer LW, Nachman RL. Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest 1973; 52: 2757-2764
• 25 Francis Jr RB, Seyfert U. Tissue plasminogen activator antigen and activity in disseminated intravascular coagulation: clinico-pathologic correlations. J Lab Clin Med 1987; 110: 541-547
• 26 Triplett DA, Brandt JT, Musgrave KA, Orr CA. The relationship between lupus anticoagulants and antibodies to phospholipid. JAMA 1988; 259: 550-554
• 27 Rapaport SI, Aas K, Owren PA. The lipid inhibitor of brain: mechanisms of its anticoagulant action and its comparison with the soybean inositol phosphatide inhibitor. J Lab Clin Med 1954; 44: 363-373
• 28 Juhan-Vague I, Moerman B, De Cock F, Aillaud MM, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984; 33: 523-530
• 29 Van Hinsbergh VW M, Bertina RM, van Wijngaarden A, van Tilburg NN, Emeis JJ, Haverkate F. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 1985; 65: 444-451
• 30 Gelehrter TD, Sznycer-Laszuk R. Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. J Clin Invest 1986; 77: 165-169
• 31 Declerck PJ, Alessi M-C, Verstreken M, Kruithof EK O, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme- linked immunosorbent assay. Blood 1988; 71: 220-225
• 32 Kruithof EK O, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70: 1645-1653
• 33 Hanss M, Collen D. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin, and histamine. J Lab Clin Med 1987; 109: 97-104